Yu, Lio
Moloney, Mairead
Tran, Alison
Zheng, Songzhu
Rogers, James
Article History
Received: 19 September 2022
Accepted: 14 November 2022
First Online: 21 November 2022
Declarations
:
: The study protocol was reviewed by an IRB committee (WIRB-Copernicus Group) and determined to be exempt from IRB approval under 45 CFR 46.104 (d)(4) as it fulfilled one or more of the exemption categories. Specifically, the information obtained is recorded by the investigator in such a manner that the identity of the human subject cannot readily be ascertained directly or through identifiers linked to the subjects, the investigator does not contact the subjects, and the investigator will not re-identify subjects. Any health information used in this study has been de-identified for use in this study. This study was performed in compliance with the pertinent sections of the Helsinki Declaration and its amendments. All methods were carried out in accordance with relevant guidelines and regulations.
: Dr. Lio Yu is the National Radiation Oncologist for SkinCure Oncology and has received research, speaking and/or consulting support from SkinCure Oncology. He has served on an advisory board for Bayer Pharmaceuticals previously. Mairead Moloney has no conflicts of interest to disclose. Dr. Alison Tran has no conflicts of interest to disclose. Songzhu Zheng has no conflicts of interest to disclose. Dr. James Rogers is a managing member of Summit Analytical, LLC, which was contracted to provide statistical analysis for this study. Dr. James Rogers received payment for the statistical analysis services he performed from, and thereby has a financial relationship with Next Step Business Services, LLC (a closely-held company owned by Dr. Lio Yu). The payment to Dr. Rogers was made to his own closely-held company known as Summit Analytical LLC).